Oragenics enters $5M ATM offering with Ladenburg Thalmann; cash $11.4M, runway through Q3 2023

ORAGENICS INC

Entered ATM sales agreement with Ladenburg Thalmann to sell up to $5M of common stock; 3% commission.
Cash and equivalents expected ~$11.4M as of Dec 31, 2022; sufficient to fund operations through Q3 2023.
Reverse stock split (1-for-60) completed Jan 20, 2023; post-split shares outstanding ~2.02M.
Plans to file IND for NT-CoV2-1 (Terra CoV-1) in US or Canada and start Phase 1 in H2 2023.
Proceeds to fund pre-clinical development of SARS-CoV-2 vaccine and lantibiotics program.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ORAGENICS INC entered into Sales Agreement with Ladenburg Thalmann & Co. Inc. valued at $5,000,000 (effective 2023-02-24).

Action: entry
Agreement: atm program
Counterparty: Ladenburg Thalmann & Co. Inc.
Value: $5,000,000
Effective: 2023-02-24

Exact text from the filing

On February 24, 2023, Oragenics, Inc. (the “Company”) entered into an At the Market Offering Agreement (the “Sales Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Agent”), pursuant to which the Company may issue and sell, from time to time, shares of its common stock (the “Shares”), depending on market demand, with the Agent acting as the sales agent or principal (the “Offering”).

View on SEC.gov

197 material agreements filed in the last 30 days. Browse all material agreements →

ORAGENICS INC filing history →

Source: SEC EDGAR

accession 0001493152-23-006001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.